CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.

The company posted quarterly losses of 71 cents per share which missed the analyst consensus estimate of 57 cents per share. The company reported quarterly sales of $1.083 million which beat the analyst consensus estimate of $493.182 thousand.

“We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and we are on track to finalize our submission in the fourth quarter 2026. We are pleased to provide this additional guidance on expected BLA completion following focused filing discussions with FDA. Manufacturing inspection readiness activities continue to progress, including our commitment to sustainable long-term supply. The quality and execution of the rolling BLA has been a top priority for us, and we are confident that we are taking all appropriate measures to ensure a successful package. This has been a tremendous undertaking, and I am extremely proud of the team for their unwavering commitment,” stated Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology.

CG Oncology shares rose 0.2% to trade at $69.74 on Monday.

These analysts made changes to their price targets on CG Oncology following earnings announcement.

  • Wedbush analyst Yun Zhong maintained CG Oncology with an Outperform rating and raised the price target from $77 to $80.
  • Truist Securities analyst Gregory Renza reiterated the stock with a Buy and raised the price target from $75 to $77.
  • RBC Capital analyst Leonid Timashev maintained the stock with an Outperform rating and raised the price target from $79 to $81.

Considering buying CGON stock? Here’s what analysts think:

Photo via Shutterstock